The aim of this study was to evaluate midterm clinical outcomes after implantation of LifeStent self-expanding nitinol stents for the treatment of femoropopliteal lesions. This retrospective, multicenter, non-randomized study examined 260 femoropopliteal lesions in 250 consecutive patients with peripheral artery disease implanted with LifeStents from April 2016 to April 2017. The prevalence of chronic total occlusion (CTO), lesion length ≥25 cm, and distal reference vessel diameter (RVD) <5 mm was 58%, 35%, and 50%, respectively. The 3-year restenosis rate in the overall population was estimated to be 72.9% and a major adverse limb event was observed in 36.9%. Multivariate analysis revealed that chronic limb-threatening ischemia (CLTI) (odds ratio [OR]: 8.04; 95% confidence interval [CI]: 1.86–34.7), CTO (OR: 4.87; 95% CI: 1.43–16.6), lesion length ≥25 cm (OR: 5.95; 95% CI: 1.11–32.0), and distal RVD <5 mm (OR: 4.43; 95% CI: 1.34–14.6) were independent risk factors for 3-year restenosis. The present study demonstrated the midterm clinical outcomes and risk factors for restenosis after implantation of the LifeStent in femoropopliteal artery lesions. CLTI, CTO, lesion length ≥25 cm, and distal RVD <5 mm predicted decreased patency after a 3-year follow-up.
AboyansVRiccoJBBartelinkMEL, et al.2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS) document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by the European Stroke Organization (ESO), the task force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC), and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763-816.
2.
LairdJRKatzenBTScheinertD, et al.Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267-76.
3.
NorgrenLHiattWRDormandyJANehlerMRHarrisKAFowkesFGR. Inter-Society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45:S5-67.
TsujimuraTTakaharaMIidaO, et al.One-year clinical outcomes following implantation of innovaTM self-expanding nitinol stents in patients with peripheral artery diseases presenting femoropopliteal artery lesions. J Atheroscler Thromb. 2019;26:847-55.
6.
IidaOTakaharaMSogaY, et al.1-year results of the ZEPHYR registry (Zilver PTX for the femoral artery and proximal popliteal artery): predictors of restenosis. JACC Cardiovasc Interv. 2015;8:1105-12.
7.
SchillingerMSabetiSLoeweC, et al.Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879-88.
8.
SchillingerMSabetiSDickP, et al.Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745-9.
9.
DickPWallnerHSabetiS, et al.Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv. 2009;74:1090-5.
10.
LairdJRKatzenBTScheinertD, et al.Nitinol stent implantation vs balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther2012;19:1-9.
11.
SogaYIidaOHiranoKYokoiHNantoSNobuyoshiM. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg. 2010;52:608-15.
12.
StonePACampbellJEFischerR, et al.Early results with lifestent implantation in RESILIENT and non-RESILIENT inclusion criteria patients. Vascular. 2015;23:225-33.
13.
LammerJZellerTHauseggerKA, et al.Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). J Am Coll Cardiol. 2013;62:1320-7.
14.
IidaOTakaharaMSogaY, et al.A novel angiographic risk score for femoropopliteal interventions. J Endovasc Ther. 2020;27:967-73.
15.
HiramoriSSogaYIidaO, et al.Relationship between clinical outcomes and vessel size in endovascular therapy for femoropopliteal lesions. J Vasc Surg. 2017;65:1690-7.
16.
SogaYIidaOHiranoK, et al.Utility of new classification based on clinical and lesional factors after self-expandable nitinol stenting in the superficial femoral artery. J Vasc Surg. 2011;54:1058-66.
17.
FujiharaMKozukiATsubakimotoY, et al.Lumen gain after endovascular therapy in calcified superficial femoral artery occlusive disease assessed by intravascular ultrasound (code study). J Endovasc Ther. 2019;26:322-30.
18.
ChenHYSinhaAKChoyJS, et al.Mis-sizing of stent promotes intimal hyperplasia: impact of endothelial shear and intramural stress. Am J Physiol Heart Circ Physiol2011;301:H2254-63.
19.
BallykPD. Intramural stress increases exponentially with stent diameter: a stress threshold for neointimal hyperplasia. J Vasc Interv Radiol. 2006;17:1139-45.
20.
ConteMSBradburyAWKolhP, et al.Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69(6S):3S-125S.
21.
ScheinertDScheinertSSaxJ, et al.Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312-5.
22.
SchlagerODickPSabetiS, et al.Long-segment SFA stenting—the dark sides: in-stent restenosis, clinical deterioration, and stent fractures. J Endovasc Ther. 2005;12:676-84.
23.
DavaineJMAzémaLGuyomarchB, et al.One-year clinical outcome after primary stenting for Trans-Atlantic Inter-Society Consensus (TASC) C and D femoropopliteal lesions (the STELLA “STEnting Long de L’Artère fémorale superficielle” cohort). Eur J Vasc Endovasc Surg. 2012;44:432-41.
24.
BosiersMTorselloGGisslerHM, et al.Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther. 2009;16(3):261-9.
25.
KobayashiNHiranoKYamawakiM, et al.Comparison of balloon angioplasty and stent implantation for femoropopliteal disease according to patient and lesion subgroup. Circ Rep. 2019;1:94-101.
26.
KayMRogoveanuRHodsonJ, et al.Factors affecting the results of superficial femoral artery stenting. Vasc Endovascular Surg. 2015;49:228-35.
27.
FeldmanDNArmstrongEJAronowHD, et al.SCAI consensus guidelines for device selection in femoral-popliteal arterial interventions. Catheter Cardiovasc Interv. 2018;92:124-40.
28.
BanerjeeSSarodeKMohammadA, et al.Femoropopliteal artery stent thrombosis: report from the excellence in peripheral artery disease registry. Circ Cardiovasc Interv2016;9:e002730.
29.
BosiersMPeetersPTessarekJDelooseKStricklerS. The Zilver® PTX® Single Arm Study: 12-month results from the TASC C/D lesion subgroup. J Cardiovasc Surg. 2013;54:115-22.
30.
SchmidtAPiorkowskiMGörnerH, et al.Drug-coated balloons for complex femoropopliteal lesions: 2-year results of a real-world registry. JACC Cardiovasc Interv. 2016;9:715-24.
31.
Müller-HülsbeckSKeirseKZellerTSchroëHDiaz-CartelleJ. Long-term results from the MAJESTIC Trial of the eluvia paclitaxel-eluting stent for femoropopliteal treatment: 3-year follow-up. Cardiovasc Intervent Radiol. 2017;40:1832-8.
32.
GrayWAKeirseKSogaY, et al.A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet. 2018;392:1541-51.
33.
StavroulakisKTorselloGBosiersMArgyriouATsilimparisNBisdasT. 2-Year outcomes of the eluvia drug-eluting stent for the treatment of complex femoropopliteal lesions. JACC Cardiovasc Interv. 2021;14:692-701.
34.
CostaFvan KlaverenDJamesS, et al.Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389:1025-34.
35.
NatsuakiMMorimotoTYamajiK, et al.Prediction of thrombotic and bleeding events after percutaneous coronary intervention: CREDO-kyoto thrombotic and bleeding risk scores. J Am Heart Assoc. 2018;7:e008708.
